度伐利尤单抗联合奥拉帕利对比度伐利尤单抗单药用于转移性非小细胞肺癌维持治疗:2期ORION研究
ORION是一项2期、随机、多中心、双盲、国际研究,评估奥拉帕利联合度伐利尤单抗用于转移性非小细胞肺癌维持治疗。401例患者接受初始度伐利尤单抗联合铂类化疗,269例无疾病进展者按1:1随机接受度伐利尤单抗联合奥拉帕利或安慰剂维持治疗。主要终点研究者评估的无进展生存期(PFS)未达统计学显著改善。
要点
- 初始化疗后269例患者被随机分组,主要终点为研究者评估的PFS。
- 度伐利尤单抗联合奥拉帕利组中位PFS为7.2个月,度伐利尤单抗联合安慰剂组为5.3个月,HR=0.76(95%CI:0.57-1.02,p=0.074),未达统计学显著。
- 两组安全性特征与度伐利尤单抗和奥拉帕利的已知特征一致,联合奥拉帕利组贫血更常见(26.1% vs 8.2%)。
核心结论
- 度伐利尤单抗联合奥拉帕利维持治疗较度伐利尤单抗单药未带来统计学显著的PFS改善,尽管观察到数值上的改善。
研究设计与样本
- ORION为2期、随机、多中心、双盲、国际研究(NCT03775486)。
- 入组转移性NSCLC(无激活EGFR或ALK异常)且ECOG体能状态0或1的患者,先接受度伐利尤单抗1500 mg静脉给药每3周一次联合铂类化疗4个周期。
- 无疾病进展者按1:1随机接受维持度伐利尤单抗1500 mg每4周一次联合奥拉帕利300 mg口服或安慰剂(均每日两次),按初始化疗期间客观缓解和肿瘤组织学类型分层。
- 2019年1月至2020年2月期间,401例接受初始化疗的患者中有269例被随机分组。
- 主要终点为研究者评估的PFS(RECIST 1.1版)。
主要发现
- 截至2021年1月11日(中位随访9.6个月),度伐利尤单抗联合奥拉帕利组中位PFS为7.2个月(95%CI:5.3-7.9),度伐利尤单抗联合安慰剂组为5.3个月(95%CI:3.7-5.8),HR=0.76(95%CI:0.57-1.02,p=0.074)。
- 安全性结果与度伐利尤单抗和奥拉帕利的已知特征一致。
- 度伐利尤单抗联合奥拉帕利组最常见的AE为贫血(26.1% vs 度伐利尤单抗联合安慰剂组8.2%)。
- 度伐利尤单抗联合奥拉帕利组对比度伐利尤单抗联合安慰剂组的3级或4级AE发生率为34.3% vs 17.9%,导致治疗终止的AE发生率为10.4% vs 4.5%,数值上更高。
关键数值与推荐
- 主要终点PFS:度伐利尤单抗联合奥拉帕利组7.2个月(95%CI:5.3-7.9)vs 度伐利尤单抗联合安慰剂组5.3个月(95%CI:3.7-5.8),HR=0.76(95%CI:0.57-1.02,p=0.074)。
- 贫血:度伐利尤单抗联合奥拉帕利组26.1% vs 度伐利尤单抗联合安慰剂组8.2%。
- 3级或4级AE:度伐利尤单抗联合奥拉帕利组34.3% vs 度伐利尤单抗联合安慰剂组17.9%。
- 导致治疗终止的AE:度伐利尤单抗联合奥拉帕利组10.4% vs 度伐利尤单抗联合安慰剂组4.5%。
临床怎么用
- 原文未据此给出推荐;研究结论为度伐利尤单抗联合奥拉帕利维持治疗较度伐利尤单抗单药未带来统计学显著的PFS改善,尽管观察到数值改善。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Increased DNA damage triggered through poly (ADP-ribose) polymerase inhibition may modify tumor immunogenicity, sensitizing tumors to immunotherapy. ORION (NCT03775486) evaluated the combination of olaparib with durvalumab as maintenance therapy in patients with metastatic NSCLC. METHODS: ORION is a phase 2, randomized, multicenter, double-blind, international study. Patients with metastatic NSCLC (without activating EGFR or ALK aberrations) and Eastern Cooperative Oncology Group performance status of 0 or 1 were enrolled to receive initial therapy with durvalumab (1500 mg intravenously; every 3 wk) plus platinum-based chemotherapy for four cycles. Patients without disease progression were then randomized (1:1) to maintenance durvalumab (1500 mg; every 4 wk) plus either olaparib (300 mg orally) or placebo (both twice daily); randomization was stratified by objective response during initial therapy and tumor histologic type. The primary end point was investigator-assessed progression-free survival (PFS) (Response Evaluation Criteria in Solid Tumors version 1.1). RESULTS: Between January 2019 and February 2020, 269 of 401 patients who received initial therapy were randomized. As of January 11, 2021 (median follow-up: 9.6 mo), median PFS was 7.2 months (95% confidence interval: 5.3-7.9) with durvalumab plus olaparib versus 5.3 months (3.7-5.8) with durvalumab plus placebo (hazard ratio = 0.76, 95% confidence interval: 0.57-1.02, p = 0.074). Safety findings were consistent with the known profiles of durvalumab and olaparib. Anemia was the most common adverse event (AE) with durvalumab plus olaparib (26.1% versus 8.2% with durvalumab plus placebo). The incidence of grade 3 or 4 AEs (34.3% versus 17.9%) and AEs leading to treatment discontinuation (10.4% versus 4.5%) was numerically higher with durvalumab plus olaparib versus durvalumab plus placebo. CONCLUSIONS: Maintenance therapy with durvalumab in combination with olaparib was not associated with a statistically significant improvement in PFS versus durvalumab alone, although numerical improvement was observed.
引用
- Ahn MJ, Bondarenko I, Kalinka E, et al. Durvalumab in Combination With Olaparib Versus Durvalumab Alone as Maintenance Therapy in Metastatic NSCLC: The Phase 2 ORION Study. J Thorac Oncol. 2023. PMID: 37390980. doi:10.1016/j.jtho.2023.06.013
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。